SCHEMBL246156

SCHEMBL246156

COc1cncc(-c2cnc(C3CCOCC3)cc2Nc2c(C)c(-c3ccccn3)nc3cc(F)cc(F)c23)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.52
PIK3CA P42336 9/20 0.39
ZAP70 P43403 1/20 0.36
PDE10A Q9Y233 1/20 0.34
PDE9A O76083 1/20 0.33
PRKDC P78527 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
MAPK14 Q16539 1/20 0.32
PIK3CB P42338 2/20 0.31
PIK3CG P48736 2/20 0.31
BRD4 O60885 1/20 0.31
PIK3R1 P27986 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249060 0.87 PIK3CD (0.60) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1
SCHEMBL249007 0.86 PIK3CD (0.48) PIK3CDPIK3CAPDE10ACYP11B1CYP11B2
SCHEMBL2713399 0.84 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1
SCHEMBL3778350 0.84 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1
SCHEMBL14849159 0.84 PIK3CD (0.48) PIK3CDPIK3CAPDE10ACYP11B1CYP11B2
SCHEMBL247672 0.83 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1
SCHEMBL247912 0.83 PIK3CD (0.48) PIK3CDPIK3CAPDE10ACYP11B1CYP11B2
SCHEMBL253882 0.82 PIK3CD (0.45) PIK3CDPIK3CAPDE10A
SCHEMBL13019399 0.82 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1
SCHEMBL243055 0.82 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885PIK3CA 28/4885ZAP70 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.